Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (9523)	11/20/2003 11:29:34 AM
From: Icebrg	Read Replies (1) of 52153

Peter Looks like SPPI has more than a single string to its bow. Have you followed Eoquin at all? I looked into this while I was still holding the stock. (I sold my shares because I felt that the market didn't consider the large number of outstanding warrants and that the share price had got ahead of itself). My impression was then that this type of very localized bladder cancer is very special and that a high degree of complete responses should be expected. A complete response in this setting might not mean as much as they do with "normal" cancers. This is the concerned abstract as posted on AACR's website. The data presented in the PR is newer as they refer to 2 twelve months' complete remissions. The design with one lesion left behind to see if the drug has any effect seems very unorthodox. Erik Edited as Peter was ahead of me.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next